Compare Novavax Inc (NVAX) vs Riot Platforms Inc (RIOT) Price & Performance

Novavax (NVAX) trades at $12.41, up 10.61% today, with strong technical momentum and bullish moving average signals. The company shows mixed fundamentals with a low P/E of 3.14 and EV/EBITDA of 1.72, but negative net income margin of -59.87% and negative shareholder equity. Recent earnings beats and FDA approvals for updated COVID-19 vaccines provide near-term catalysts.

Investment outlook remains speculative with significant execution risks despite analyst optimism (74% buy ratings). The company's pivot to Matrix-M adjuvant licensing and partnership model offers growth potential, but negative cash flow and high debt levels pose substantial financial risk. Stock appears undervalued on some metrics but requires careful risk management.

RIOT stock trades at $16.69, down 9.98% with bearish technical signals despite strong analyst support. The company shows concerning fundamentals with negative net income margins (-196.28%) and ROE (-48.24%), though revenue reached $647.44M in 2025. Recent strategic shift to data center services with $9.8B in contracted lease revenue through 2048 provides long-term visibility.

While analyst consensus remains strongly bullish (94.74% buy ratings) with $31.64 price target, execution risks persist given consecutive earnings misses and negative cash flow. The AI infrastructure pivot offers growth potential but requires careful monitoring of profitability improvements and Bitcoin market volatility exposure.